Zymeworks signs licensing and development partnership with Roche for ZW209
Zymeworks announced a deal with Roche granting the Swiss firm worldwide rights to develop and sell ZW209, a trispecific T‑cell engager targeting DLL3. Roche will pay $55 million up‑front, $40 million when a Phase 1b study starts, and up to $718 million in development, commercial and sales milestones, plus tiered royalties. Zymeworks will run the Phase 1a monotherapy trial, after which Roche will fund and lead all further development and commercialization. The transaction remains subject to Hart‑Scott‑Rodino antitrust clearance and other customary closing conditions.
Why it matters
The upfront cash and potential milestone payments provide immediate and future funding for Zymeworks, while Roche’s involvement could accelerate ZW209’s development and broaden its market reach. Investors should note that the deal’s total value could reach $813 million, but the full amount depends on the program’s success and regulatory approvals.
Key facts
- 1Zymeworks will receive an upfront payment of $55 million from Roche. tradingview.com
- 2A $40 million payment is payable when the Phase 1b trial of ZW209 is initiated. tradingview.com
- 3Milestone payments of up to $718 million are possible for development, commercial and sales achievements. tradingview.com
- 4Roche will fund the Phase 1a monotherapy trial and take exclusive global rights to develop and commercialize ZW209. tradingview.com
- 5The agreement is subject to the expiration or termination of the Hart‑Scott‑Rodino waiting period and other customary closing conditions. tradingview.com
- 6Zymeworks will retain tiered royalties ranging from high single‑digit to mid‑teen percentages on future net sales. tradingview.com
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.